These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and malignant tumors of the lung. Sasaki M; Kuwabara Y; Yoshida T; Nakagawa M; Koga H; Hayashi K; Kaneko K; Chen T; Ichiya Y; Masuda K Ann Nucl Med; 2001 Oct; 15(5):425-31. PubMed ID: 11758947 [TBL] [Abstract][Full Text] [Related]
47. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET. Tatsumi M; Yutani K; Watanabe Y; Miyoshi S; Tomiyama N; Johkoh T; Kusuoka H; Nakamura H; Nishimura T J Nucl Med; 1999 Apr; 40(4):566-73. PubMed ID: 10210214 [TBL] [Abstract][Full Text] [Related]
48. FDG PET/CT evaluation of pathologically proven pulmonary lesions in an area of high endemic granulomatous disease. Sebro R; Aparici CM; Hernandez-Pampaloni M Ann Nucl Med; 2013 May; 27(4):400-5. PubMed ID: 23400394 [TBL] [Abstract][Full Text] [Related]
49. Comparison of [(18)F]FDG PET and (201)Tl SPECT in evaluation of pulmonary nodules. Higashi K; Ueda Y; Sakuma T; Seki H; Oguchi M; Taniguchi M; Taki S; Tonami H; Katsuda S; Yamamoto I J Nucl Med; 2001 Oct; 42(10):1489-96. PubMed ID: 11585862 [TBL] [Abstract][Full Text] [Related]
51. Differentiation between malignancy and inflammation in pulmonary ground-glass nodules: The feasibility of integrated (18)F-FDG PET/CT. Chun EJ; Lee HJ; Kang WJ; Kim KG; Goo JM; Park CM; Lee CH Lung Cancer; 2009 Aug; 65(2):180-6. PubMed ID: 19155090 [TBL] [Abstract][Full Text] [Related]
52. Pulmonary abnormalities and PET data analysis: a retrospective study. Lowe VJ; Duhaylongsod FG; Patz EF; Delong DM; Hoffman JM; Wolfe WG; Coleman RE Radiology; 1997 Feb; 202(2):435-9. PubMed ID: 9015070 [TBL] [Abstract][Full Text] [Related]
53. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases]. Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458 [TBL] [Abstract][Full Text] [Related]
54. The role of FDG PET-CT in differential diagnosis of pleural pathologies. Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687 [TBL] [Abstract][Full Text] [Related]
55. Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity. Cloran FJ; Banks KP; Song WS; Kim Y; Bradley YC Lung Cancer; 2010 Apr; 68(1):66-71. PubMed ID: 19559496 [TBL] [Abstract][Full Text] [Related]
56. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. Delbeke D; Rose DM; Chapman WC; Pinson CW; Wright JK; Beauchamp RD; Shyr Y; Leach SD J Nucl Med; 1999 Nov; 40(11):1784-91. PubMed ID: 10565771 [TBL] [Abstract][Full Text] [Related]
57. Relation between nodule size and 18F-FDG-PET SUV for malignant and benign pulmonary nodules. Khalaf M; Abdel-Nabi H; Baker J; Shao Y; Lamonica D; Gona J J Hematol Oncol; 2008 Sep; 1():13. PubMed ID: 18808716 [TBL] [Abstract][Full Text] [Related]
58. Dual-time-point Huang YE; Huang YJ; Ko M; Hsu CC; Chen CF Ann Nucl Med; 2016 Nov; 30(9):652-658. PubMed ID: 27492555 [TBL] [Abstract][Full Text] [Related]
59. Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Hickeson M; Yun M; Matthies A; Zhuang H; Adam LE; Lacorte L; Alavi A Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1639-47. PubMed ID: 12458399 [TBL] [Abstract][Full Text] [Related]
60. 18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study. Carretta A; Landoni C; Melloni G; Ceresoli GL; Compierchio A; Fazio F; Zannini P Eur J Cardiothorac Surg; 2000 Apr; 17(4):377-83. PubMed ID: 10773558 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]